Radiation Oncology
Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.
Recent Discussions
What are your shift tolerances for fractionated SBRT and SRS treatments?
I generally use Shift more than PTV margin as an indication for repeat imaging.
Do you routinely boost the lumpectomy cavity for HER2-positive breast cancer in the absence of other risk factors?
I do tend to boost although absolute benefit for node negative favorable ER PR positive her2 neu positive breast cancer is probably minimal. For these patients, we also offer APBI routinely.
How would you treat a locally recurrent NSCLC abutting the heart that was previously treated with conventional chemoRT?
Like any reirradiation case, there is no one correct answer regarding this difficult scenario. The amount of time elapsed since prior RT, how much dose was received by the heart from the conventional treatment, cardiac/pulmonary comorbidities, life expectancy, performance status, other medical/surgi...
Would you cover presacral lymph-nodes in endometrial cancer patients with locally advanced disease (IIIC2 disease) who received neo-adjuvant chemotherapy prior to resection with no residual disease on pathology?
For IIIC2 endometrial cancer, we have included presacral lymph nodes routinely. There are no studies to compare with and without presacral lymph to my knowledge.
For a lymph node negative nasopharyngeal EBV(+), cT3N0, what lymph node levels would you electively cover after a good response to induction chemotherapy?
I think one can consider omitting the low neck for N0 neck. I would make sure restaging scans are done prior to the start of radiation post induction chemotherapy.
Is history of radioactive iodine treatment for thyroid cancer a contraindication to receive XRT for prostate cancer?
Not a contraindication. Thyroid patients can get multiple rounds of RAI, and be eligible for external beam to the HN area, so there would be no contraindication in other sites of the body.
What is the highest dose to which you treat a locally advanced esophageal cancer with a stent in place?
Shin et al., PMID 15640412 Since it appears that covered temporary or permanent stents are relatively safe with radiotherapy and that the palliative and curative doses are the same, 5040 cGy should be reasonable.The addition of chemotherapy will definitely increase toxicity but may be considered for...
How does pathological skin involvement (i.e. nipple, epidermis) but not clinical skin involvement change your recommendations regarding PMRT in the absence of other risk factors?
Not by itself, as sometimes it is just a function of location rather than stage and biology but in conjunction with other factors, I do consider for possible PMRT. Katz et al., PMID 11395242
How do you approach the treatment of breast cancer with enlarged but indeterminate breast nodes?
Since T2 no, pre-op chemo plus IO and then surgery which would involve SNLN plus removal of targeted node (even though negative would add clip at biopsy).
How would you manage recurrent laryngeal papillomatosis requiring multiple resections of lesions with pathology never revealing any degree of dysplasia?
I am not aware of any study of radiotherapy for laryngeal papillomatosis. It is not included in the usual indications for radiotherapy of benign disease. Thus, no radiotherapy. An alternative to repeated surgeries may be photodynamic laser (Motz and Hillel, PMID 27242951).